利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

139 条记录 (耗时 0.024 秒)

    AUGURIN IMMUNOASSAY
    4.
    发明授权
    AUGURIN IMMUNOASSAY 有权

    公开(公告)号：EP3019875B1

    公开(公告)日：2018-10-10

    申请号：EP14737268.4

    申请日：2014-07-10

    申请人： B.R.A.H.M.S GmbH

    发明人： STRUCK, Joachim ,  ZIERA, Tim

    IPC分类号： G01N33/74 ,  C07K16/26 ,  C12N5/12

    CPC分类号： G01N33/74 ,  C07K16/26 ,  C07K2317/34 ,  C12N5/12 ,  G01N2333/575

    摘要： The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1.

    PREDICTION OF OUTCOME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    6.
    发明公开
    PREDICTION OF OUTCOME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 审中-公开
    慢性阻塞性肺疾病患者结局预测

    公开(公告)号：EP3232201A1

    公开(公告)日：2017-10-18

    申请号：EP17000604.3

    申请日：2013-02-26

    申请人： B.R.A.H.M.S GmbH

    发明人： GIERSDORF, Sven ,  TAMM, Michael ,  STOLZ, Daiana

    IPC分类号： G01N33/68 ,  G01N33/74

    CPC分类号： G01N33/74 ,  G01N33/6884 ,  G01N33/6893 ,  G01N2333/58 ,  G01N2333/585 ,  G01N2800/122 ,  G01N2800/50 ,  G01N2800/52

    摘要： The present invention relates to a method for the prognosis and/or risk assessment and/or monitoring of therapy and/or management of patients with COPD the method comprising the steps of:
    i) providing a sample of a bodily fluid from said patient,
    ii) determining in said sample the level of at least one biomarker, selected from the group consisting of pro-adrenomedullin (proADM), pronatriuretic peptide, pro-Vasopressin (proAVP) and Pro-calcitonin (PCT) or fragments thereof of at least 12 amino acids in length,
    iii) determining one, two or three of the BODE-index parameters body-mass index (BMI, parameter B), degree of airflow obstruction (FEV 1 , parameter O), dyspnea (parameter D) and exercise capacity (parameter E),
    iv) correlating said level of said at least one biomarker determined in step ii), in combination with said one, two or three BODE-index parameters determined in step iii) to the prognosis and/or risk assessment and/or monitoring of therapy and/or management of patients with COPD.

    摘要翻译： 本发明涉及用于COPD患者的治疗和/或管理的预后和/或风险评估和/或监测的方法，所述方法包括以下步骤：i）提供来自所述患者的体液样品，ii ）测定所述样品中至少一种选自至少12个氨基酸的前肾上腺髓质素（proADM），前导肽，前加压素（proAVP）和前降钙素（PCT）或其片段的生物标志物或其片段的水平 iii）确定BODE指数参数体重指数（BMI，参数B），气流阻塞程度（FEV1，参数O），呼吸困难（参数D）和运动能力（参数B）中的一个，两个或三个 E），iv）将步骤ii）中确定的所述至少一种生物标志物的所述水平，与步骤iii）中确定的所述一种，两种或三种BODE-指标参数相结合，与预后和/或风险评估和/或监测 治疗和/或患者的管理 慢性阻塞性肺病。